Novo Nordisk(US:NVO) GLP1减重宝典·2025-12-21 11:28Core Viewpoint - Novo Nordisk's GLP-1 drug Wegovy has received conditional marketing authorization from Health Canada for treating adults with moderate to severe liver fibrosis (F2-F3) associated with non-alcoholic steatohepatitis (NASH), marking its expansion into liver disease treatment beyond obesity and metabolic disorders [5]. Regulatory Perspective - The conditional approval indicates that further research is needed to validate long-term efficacy and safety, reflecting a cautious support from regulators for products with clear potential clinical benefits in the NASH field, which currently lacks established treatment options [7]. Market and Medical Value - As Wegovy's indications continue to expand, its positioning within the metabolic disease spectrum is evolving from a singular weight loss and diabetes treatment to a comprehensive therapeutic tool addressing obesity, metabolic syndrome, and related organ damage, thereby stretching its commercial and medical value boundaries in the global market [7].